nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.08.2008 | Original Article

In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines

verfasst von: Marisa A. Navo, Judith A. Smith, Anjali Gaikwad, Thomas Burke, Jubilee Brown, Lois M. Ramondetta

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the growth inhibitory effects of mifepristone on endometrial cancer cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human endometrial cancer cell lines.

Methods

The human endometrial cancer cell lines, HEC-1-A and Ishikawa, were cultured in vitro. MTT assays were completed in order to estimate the IC₅₀ of mifepristone. Both cell lines were then treated with the respective IC₅₀ values. Immunohistochemistry assays were performed to investigate the expression of estrogen receptors alpha and beta (ERα/β), progesterone receptor alpha and beta (PR α/β), cyclooxygenase-2 (COX-2), bax, p53, and bcl-2. Flow cytometry analysis was performed to study cell cycle arrest and apoptosis.

Results

The estimated IC₅₀ of mifepristone for HEC-1-A and Ishikawa was found to be 16 and 19 μg/ml respectively. At this concentration, there was no change in either ERα/β or PR α/β in Ishikawa. However, PR β expression increased with time of treatment in HEC-1-A. Expression of p53 was increased with duration of treatment in both cell lines. Consequently a decrease in bcl-2 and an increase in COX-2 expression were seen in HEC-1-A and Ishikawa cells, respectively. Lastly, flow cytometry analysis confirmed an accumulation of cells in G0 phase after 72 h of treatment in both cell lines.

Conclusions

Mifepristone demonstrates activity in both HEC-1-A and Ishikawa cells at clinically relevant concentrations based on an oral human dose of about 200 mg/day. While its mechanism of action remains unknown, this data supports an increase in apoptosis that may be due to p53 activation rather than hormone receptor mediation. Additional studies are needed to help further identify mifepristone mechanism of action.

Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2006. CA Cancer J Clin 57:43–66PubMedCrossRef

Ellenson LH, Wu TC (2004) Focus on endometrial and cervical cancer. Cancer Cell 5:533–538PubMedCrossRef

Humber C, Tierney J, Symonds P et al (2005) Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev (4):CD003915

Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11:1531–1543PubMed

Gadducci A, Gargini A, Palla E, Fanuchhi A, Genazzani AR (2005) Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 20:200–208PubMedCrossRef

Danco Laboratories LLC (2005) Mifeprex (mifepristone) package insert. New York

Spitz IM (2003) Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 68:981–993PubMedCrossRef

Spitz IM, Robbins A (1998) Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus. Hum Reprod Update 4:584–593PubMedCrossRef

Steinauer J, Pritts EA, Jackson R, Jacoby AF (2004) Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 103:1331–1336PubMed

10.

Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS (2006) Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size. Obstet Gynecol 108:1381–1387PubMed

11.

Mahajan DK, London SN (1997) Mifepristone (RU486): a review. Fertil Steril 68:967–976PubMedCrossRef

12.

Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS (2003) Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 101:243–250PubMedCrossRef

13.

Han S, Sidell N (2003) RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J Clin Endocrinol Metab 88:713–719PubMedCrossRef

14.

Jiang J, Wu R, Wang Z, Sun H, Xu Z, Xiu H (2002) Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 77:995–1000PubMedCrossRef

15.

Li A, Felix JC, Minoo P, Amezcua CA, Jain JK (2005) Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril 84:202–211PubMedCrossRef

16.

Schneider CC, Gibb RK, Taylor DD, Wan T, Gercel-Taylor C (1998) Inhibition of endometrial cancer cell lines by mifepristone (RU486). J Soc Gynecol Invest 5:334–338CrossRef

17.

Mirkin S, Archer DF (2004) Effects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the endometrial effects of mifepristone. Contraception 70:327–333PubMedCrossRef

18.

Kamradt MC, Mohideen N, Vaughan AT (2000) RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol 77:177–182PubMedCrossRef

19.

Smith JA, Gaikwad A, Ramondetta LM, Wolf JK, Brown J (2006) Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. Gynecol Oncol 103:518–522PubMedCrossRef

20.

Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S, Sidell N (2000) RU486-induced growth inhibition of human endometrial cells. Fertil Steril 74:1014–1019PubMedCrossRef

21.

Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV (2003) Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol 23:369–380PubMed

22.

Lin VC-L, Aw SE, Ng EG, Ng EH-L, Tan MG-K (2001) Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues. Br J Cancer 85:1978–1986PubMedCrossRef

23.

Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein (2004) Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res 10:5215–5225PubMedCrossRef

24.

Lessey BA, Ilesanmi AO, Castelbaum AJ et al (1996) Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the α1 integrin. Steroid Biochem Molec Biol 59:31–39CrossRef

25.

Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F (1984) The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 59:25–28PubMedCrossRef

26.

Rae MT, Niven D, Critchley H, Harlow CR, Hillier SG (2004) Antiinflammatory steroid action in human ovarian surface epithelial cells. J Clin Endocrinol Metab 89:4538–4544PubMedCrossRef

27.

Chivers JE, Cambridge LM, Catley MC et al (2004) Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E release. Eur J Biochem 271:4042–4052PubMedCrossRef

28.

Rose FV, Barnea ER (1996) Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogen 12:999–1003

29.

Sun Y (2006) p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 45:409–415PubMedCrossRef

30.

Skildum A, Faivre E, Lange CA (2005) Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 19:327–329PubMedCrossRef

Titel: In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines
verfasst von: Marisa A. Navo
Judith A. Smith
Anjali Gaikwad
Thomas Burke
Jubilee Brown
Lois M. Ramondetta
Publikationsdatum: 01.08.2008
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2008
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0628-z

Springer Medizin

In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N 1 , N 11 diethylnorspermine

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors

A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors

Influence of carboplatin infusion on osteosarcoma blood flow

Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells

Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie